Sign In
Buy IMGN
$31.23
+0 (+0%)
At Close: May 08, 2024
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results
04:01pm, Thursday, 14'th Oct 2021
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 01'st Oct 2021
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors
04:01pm, Wednesday, 22'nd Sep 2021
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors
ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q2 2021 Results - Earnings Call Transcript
02:05pm, Friday, 30'th Jul 2021
ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q2 2021 Results - Earnings Call Transcript
ImmunoGen (IMGN) Reports Q2 Loss, Misses Revenue Estimates
09:08am, Friday, 30'th Jul 2021
ImmunoGen (IMGN) delivered earnings and revenue surprises of 16.67% and -10.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results
06:30am, Friday, 30'th Jul 2021
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results
Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for
04:05pm, Friday, 23'rd Jul 2021
ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference
04:30pm, Thursday, 20'th May 2021
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference
ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q1 2021 Results - Earnings Call Transcript
01:24pm, Monday, 10'th May 2021
ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q1 2021 Results - Earnings Call Transcript
ImmunoGen (IMGN) Q1 Earnings Top, Pivotal Studies Delayed
12:01pm, Monday, 10'th May 2021
ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. Meanwhile, data readouts from pivotal studies on lead candidate get delayed due to COVID-19.
ImmunoGen (IMGN) Reports Q1 Loss, Misses Revenue Estimates
08:16am, Monday, 10'th May 2021
ImmunoGen (IMGN) delivered earnings and revenue surprises of 10.53% and -7.15%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Immunogen: Q1 Earnings Insights
07:08am, Monday, 10'th May 2021
Shares of Immunogen (NASDAQ:IMGN) decreased 1.8% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were unchanged 0.00% over the past year to ($0.17), w
ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results
06:30am, Monday, 10'th May 2021
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results
ImmunoGen: Turning Around Amid A Bearish Environment
11:46am, Wednesday, 28'th Apr 2021
Riding powerful fundamental improvement, ImmunoGen has made strong turnaround progress. With the upcoming data release for SORAYA and MIRASOL, you can expect ImmunoGen to break the bearish trend to tr
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2021 Operating Results
04:01pm, Monday, 26'th Apr 2021
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its First Quarter 2021 Operating Results
